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AMPKMetformin is a commonly-used treatment for type 2 diabetes, whose mechanism of action has been linked, in
part, to activation of AMP-activated protein kinase (AMPK). However, little is known regarding its effect on
circadian rhythms. Our aim was to evaluate the effect of metformin administration on metabolism, locomotor
activity and circadian rhythms. We tested the effect of metformin treatment in the liver and muscle of young
lean, healthy mice, as obesity and diabetes disrupt circadian rhythms. Metformin led to increased leptin and
decreased glucagon levels. The effect of metformin on liver and muscle metabolism was similar leading to
AMPK activation either by liver kinase B1 (LKB1) and/or other kinases in the muscle. AMPK activation
resulted in the inhibition of acetyl CoA carboxylase (ACC), the rate limiting enzyme in fatty acid synthesis.
Metformin also led to the activation of liver casein kinase I α (CKIα) and muscle CKIε, known modulators of
the positive loop of the circadian clock. This effect was mainly of phase advances in the liver and phase delays
in the muscle in clock and metabolic genes and/or protein expression. In conclusion, our results demonstrate
the differential effects of metformin in the liver and muscle and the critical role the circadian clock has in
orchestrating metabolic processes.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The mammalian master circadian clock is located in the hypotha-
lamic suprachiasmatic nuclei (SCN), but there are similar clocks in
peripheral tissues [1,2]. The core clock mechanism is composed of the
transcription factor CLOCK which interacts with BMAL1 to drive the
transcription of a large number of genes. These genes encode the
PERIOD (PER1, PER2 and PER3) and CRYPTOCHROME (CRY1 and CRY2)
proteins that inhibit CLOCK:BMAL1-mediated transcription, thus
serving as the negative feedback loop [2]. Other transcriptional loops
involve the control of PER and BMAL1 protein stability by casein kinase
1ε (CKIε) phosphorylation [3]. Bmal1 expression is also regulated nega-
tively by reverse orientation c-erbA-1 α (REV-ERBα) and positively by
receptor-related orphan receptor α (RORα) via the RORE (ROR re-
sponse element) [4,5].
Metabolism is an important feedback to the circadian clock in the
peripheral tissues, synchronizing it to environmental cues, such as food
availability [6]. In addition, the core clockmechanism is tightly linked to
metabolic pathways: 1) REV-ERBα, RORα, and PPARα (peroxisome
proliferator-activated receptor α), regulators of lipogenesis and lipid
metabolism, regulate Bmal1 transcription [4,5,7]. 2) In turn, CLOCK:+972 8 936 3208.
l rights reserved.BMAL1 heterodimer regulates the expression of Rev-erbα, Rorα, and
Pparα [4,5,7–9]. 3) PPARγ co-activator 1α (PGC-1α), which regulates
energy metabolism, stimulates the expression of the clock genes Bmal1
and Rev-erbα; mice lacking PGC-1α show abnormal diurnal rhythms of
activity, body temperature, and metabolic rate [10]. 4) Activation of
adenosine monophosphate-activated protein kinase (AMPK), a sensor
of low energy and nutrient state in the cell, leads to altered circadian
rhythms by destabilizing the negative limb of the circadian clock, PERs
and CRYs [11,12].
AMPK is activated when cellular ATP levels are depleted and
switches the cell from anabolic to catabolic pathways [13]. Hypotha-
lamic AMPK regulates energy intake by mediating the opposing
effects of orexigenic and anorexigenic signals [14]. In the peripheral
tissues, AMPK is phosphorylated and activated under elevated AMP
levels by liver kinase B1 (LKB1) [15] following hormonal signals, such
as adiponectin [16]. Consequently, activated AMPK phosphorylates
and, thus, inactivates acetyl-CoA carboxylase (ACC), the key enzyme
in fatty acid synthesis. Reduced fatty acid synthesis as well as
activation of PPARα result in mitochondrial fatty acid oxidation [16].
Metformin is a commonly-used treatment for type 2 diabetes
(T2DM), whose mechanism of action has been linked, in part, to the
activation of AMPK [17,18]. However, little is known about its effect
on circadian rhythms. As metformin affects metabolism and metab-
olism is interlinked to the circadian clock, our aim in this study was to
evaluate the effect of metformin administration on circadian rhythms.
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the effect of metformin on the metabolic state, locomotor activity and
circadian rhythms in the liver and muscle of young lean mice.
2. Methods
2.1. Animals and experimental design
8-week-old C57BL/6 male mice (Harlan Laboratories, Jerusalem,
Israel) were housed in a temperature- and humidity-controlled facility
(23–24 °C, 60% humidity). Mice were entrained to 12 h light and 12 h
darkness (LD) for 2 weeks and then were randomly assigned to either
the control (n=24) or metformin treatment (164 mg/kg/day; n=24)
group for 6 weeks. Metformin was provided in the drinking water
designed to achieve themaximum recommended dose of metformin for
humans per basal water intake. Body weight was recorded weekly and
on the second and seventh week fasting blood glucose levels were
determined with a digital “Optium Xceed” glucometer (Abbott Labora-
tories, Alameda, CA, USA). After 6 weeks of treatment, mice were placed
on a 12-h fast and subsequently every 3 h around the circadian cycle
animals were tested for blood glucose. CT0/24 time-points are double-
plotted in the ﬁgures. On the day of sacriﬁce, micewere anesthetized by
intraperitoneal injection of ketamine/xylazine (100/7.5 mg/kg) under
dim red light in total darkness (DD). Liver and muscle tissues were
removed and immediately frozen in liquid nitrogen and stored at
−80 °C for further analysis. Serum was collected and stored at−20 °C
for further analyses. Animals were humanely killed according to the
strict guidelines of the Hebrew University. The Principles of Laboratory
Animal Care (NIH publication no. 85–23, revised 1985) were followed.
2.2. Enzyme-linked immunosorbent assay (ELISA)
Serum hormone levels were determined for ghrelin (Linco Research
Inc., St Charles,MO,USA), insulin (Mercodia, Uppsala, Sweden), glucagon
(Phoenix Pharmaceuticals Inc., Burlingame, CA, USA) and leptin (R&D
Systems Inc., Minneapolis, MN, USA) using ELISA kits. All assays were
performed according to the manufacturer's instructions.
2.3. Enzymatic colorimetric test
Serum triglycerides and cholesterol levels were determined by
Cobas® kits (Roche Diagnostics, Burgess Hill, UK) and analyzed in a
Roche/Hitachi analyzer (Roche Diagnostics). Assays were performed
according to the manufacturer's instructions.Table 1
Biochemical measurements taken on the last day of the experiment.
Metformin-treated
group (n=24)
Control group
(n=24)
p Value
Body weight 25.2±0.46 24.8±0.51 0.54
Food intake (/kg/day) 0.223±0.003 0.221±0.002 0.61
Water intake (/kg/day) 0.105±0.008 0.082±0.002 0.04
Fasting glucose 69±4.3 61.75±2.9 0.17
Cholesterol 124.9±5.1 122.5±5.5 0.7
HDL 108.6±4 106.3±4.7 0.7
TG 123.3±9.6 131.7±13.3 0.6
Insulin mIU 11.54±0.87 13.15±1.51 0.35
Glucagon (ng/ml) 1.13±0.08 0.53±0.03 b0.0001
HOMA-IR 1.97±0.17 2.18±0.37 0.59
Ghrelin (ng/ml) 2.88±0.26 2.76±0.76 0.76
Leptin (ng/ml) 4.73±0.55 6.77±0.47 0.006
Adiponectin (ng/ml) 304.2±9.5 349.5±15.5 0.018
Values are means±standard error.
HDL, high density lipoprotein; TG, triglyceride; HOMA-IR, homeostasis model assessment
insulin resistance.2.4. Homeostasis model assessment of insulin resistance (HOMA-IR)
The insulin-resistance index using fasting serum insulin and plasma
glucose levels was determined by the homeostasis model assessment
(HOMA) parameter [21].Fig. 1. Effect of metformin on circadian triglycerides and hormone expression. Levels of
triglyceride (A), insulin (B), glucagon (C), leptin (D) and ghrelin (E) were determined every
3 h around the circadian cycle in control (C, black circles) or metformin-treated (Met, white
circles) mice. The white and gray bars designate the subjective day and night, respectively.
Values are mean±SE, n=3 per time point in each group. CT, circadian time.
Fig. 2. Effect of metformin on circadian rhythms and average protein levels of AMPK and pAMPK in the hypothalamus. A. Average daily levels of AMPK and pAMPK proteins. B. Circadian
AMPK protein expression. C. Circadian pAMPK protein expression. AMPK and pAMPK proteins were analyzed byWestern blotting and quantiﬁed using actin as loading control. For total
daily levels, all time-points were averaged. Hypothalamus was collected in total darkness every 3 h around the circadian cycle from control (C, black circles and columns) or metformin-
treated (Met, white circles and columns) mice. The white and gray bars designate the subjective day and night, respectively. Values are mean±SE, n=3 per time-point in each group.
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RNA extraction and qPCR were performed as was described [22].
Primers (Table S1) were designed with Primer express v.2 (Applied
Biosystems, Foster City, CA) and validated by a standard curve and
dissociation curve of the product. The fold change in target gene ex-
pression was calculated by the 2−ΔΔCt relative quantiﬁcation method
(Applied Biosystems).
2.6. Western blot analysis
Liver tissue samples were homogenized, run on an SDS-
polyacrylamide gel and transferred onto nitrocellulose mem-
branes, as was described [22]. Blots were incubated with AMPK/
pAMPK, ACC/pACC, LKB1/pLKB1, CK1α antibodies (Cell Signaling
Technology, Beverly, MA, USA) and CKIε (Abcam, Cambridge, UK) and
after several washes, with horseradish peroxidase-conjugated second-
ary antibody (Pierce, Rockford, IL, USA). The immune reaction was
detected by enhanced chemiluminescence (ECL). Finally, bands were
quantiﬁed by scanning and densitometry and expressed as arbitrary
units.
2.7. Statistical analyses
All results are expressed as means±SE. A two-way analysis of
variance (ANOVA) (time of day×treatment) was performed and a
least-signiﬁcant difference t-test was used for comparison between
the control and metformin-treated groups. One-way ANOVA was
used to analyze circadian pattern with several time-points. Statistical
analysis was performed with JMP software (version 8.1, SAS Institute
Inc. Cary, NC, USA). The acrophase and p-value of gene oscillation
were calculated using the free Cosinor analysis software (Version 2.3)
available at http://www.circadian.org/softwar.html. The signiﬁcance
level for all analyses was set at pb0.05.
3. Results
Mice were fed regular chow and metformin was added to the
drinking water for 6 weeks. As obesity affects circadian rhythms
[19,20,23], we used lean healthy mice to measure the effect of met-
formin without obesity being a confounder. When evaluating metfor-
min effects, we calculated 8 time-points encompassing the entire
circadian cycle to achieve an accurate assessment of daily mean
Asterisk denotes signiﬁcant difference (pb0.05). CT, circadian time.Fig. 3. Effect of metformin on clock gene expression in the liver and muscle. Expression levels o
collected in total darkness every 3 h around the circadian cycle from control (C, black circles a
reverse-transcribed and its levels were determined by real-time PCR. For total daily levels, all ti
respectively. Values are mean±SE, n=3 per time-point in each group. Asterisk denotes signiﬁlevels, as a single point might represent the peak or trough of the
circadian expression.
3.1. Body weight, food intake and daily locomotor activity of metformin-
treated mice
Mean body weight (Fig. S1A) and food intake (Fig. S1B) throughout
the experiment and on the last day (Table 1) did not differ between the
metformin-treated and control mice. There was a small but signiﬁcant
reduction in water intake in the metformin-treated group (Student's
t-test, pb0.05) (Table 1). To study the effect on the overall daily
rhythms, we evaluated the effect of metformin treatment on food
intake rhythms and locomotor activity. Metformin administration
did not affect mouse 24-h food intake rhythms (Fig. S1C) or
locomotor activity (Fig. S1D) under light–dark (LD) conditions.
Under total dark (DD) conditions both groups exhibited free-running
(Fig. S1D) with no effect on the endogenous circadian period (tau)
(taucontrol=23.8±0.03 h, taumetformin=23.7±0.09 h).
3.2. Serum measurements of metformin-treated mice
As expected from healthy lean mice, fasting glucose was similar
throughout the experiment (Fig. S1E) and on the last day (Table 1).
Similarly, total cholesterol and high density lipoprotein (HDL) levels did
not differ between the groups (Table 1). Also triglyceride (TG) levels did
not differ between the groups (Table 1), and they exhibited a robust
daily rhythmwith a peak at CT5 (Cosinor analysis, pb0.05), toward the
middle of the subjective day, in both groups (Fig. 1A). Insulin levels did
not differ between the groups, but glucagon levels were reduced
(Student's t-test, pb0.001) (Table 1). As glucose and insulin levels did
not differ between the groups HOMA-IR was not different (Table 1).
Insulin exhibited a daily rhythm and peaked at CT8 (Cosinor analysis,
pb0.05); metformin administration resulted in a 3-h phase advance of
insulin (Fig. 1B). Glucagon did not exhibit a daily rhythm in both groups
(One-wayANOVA, p>0.05), and its levelswere consistently lower at all
time-points followingmetformin treatment (Fig. 1C). Ghrelin levels did
not differ between the groups, but leptin levels were increased
(Student's t-test, pb0.01) in metformin-treated mice (Table 1). Met-
formin treatment also resulted in a 6 h phase advance of leptin ex-
pression, from the beginning of the subjective night to the end of the
subjective day (Cosinor analysis, pb0.05) (Fig. 1D). The amplitude of
leptin was increased by 50% (Cosinor analysis, pb0.05) (Fig. 1D),
corresponding to the overall increased daily levels (Table 1). The phasef Per1, Per2, Cry1, Clock, Bmal1, Rev-erbα and RORα. Liver and gastrocnemius muscle were
nd columns) or metformin-treated (Met, white circles and columns) mice. Total RNA was
me-points were averaged. Thewhite and gray bars designate the subjective day and night,
cant difference (pb0.05). CT, circadian time.
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Fig. 4. Effect of metformin on circadian rhythms and average mRNA and protein levels of the AMPK pathway in the liver. A. Ampk, Lkb1, Acc and Ck1εmRNA oscillation and daily average
levels. B. AMPK, LKB1, ACC, CK1ε and CK1α protein oscillation and daily average levels. Liver was collected in total darkness every 3 h around the circadian cycle from control (C, black
circles and columns) ormetformin-treated (Met, white circles and columns)mice. Total RNAwas extracted, reverse-transcribed and expression levelswere determined by real-time PCR.
Protein levels were analyzed byWestern blotting and quantiﬁed using actin as loading control. The white and gray bars designate the subjective day and night, respectively. Values are
mean±SE, n=3 per time-point in each group. Asterisk denotes signiﬁcant difference (pb0.05). CT, circadian time.
1800 M. Barnea et al. / Biochimica et Biophysica Acta 1822 (2012) 1796–1806of ghrelinwas not affected bymetformin treatmentwith a peak at CT17
during the subjective night in both groups, yet its amplitude decreased
by 26% (One-way ANOVA, pb0.05) (Fig. 1E).3.3. Effect of metformin on hypothalamic AMPK
We next tested the effect of metformin on hypothalamic AMPK, as
AMPK is an energy gauge in this brain region. Metformin treatment
resulted in reduced AMPK levels and a reduction in its active phos-
phorylated form (pAMPK) (Student's t-test, pb0.01) (Fig. 2A). Metfor-
min also resulted in a 3-h phase advance in AMPK circadian oscillation
(Cosinor analysis, pb0.05) (Fig. 2B), although pAMPK rhythmicity was
unaffected (Fig. 2C).3.4. Effect of metformin on clock genes in the liver and muscle
All clock genes oscillated in the liver andmuscle in the presence or
absence of metformin (Fig. 3, Table S2). Analysis of clock gene ex-
pression revealed that liver Per1, Clock, Bmal1 and Rorα and muscle
Bmal1 and Rev-erbα exhibited a 3-h phase advance after metformin
treatment (Cosinor analysis, pb0.05) (Fig. 3, Tables S2 and S3). Met-
formin did not alter the phase of liver Cry1 and Rev-erbα and muscle
Clock (Cosinor analysis, pb0.05). Liver Per2 and muscle Per1, Rora and
Cry1 displayed a phase delay as a result of metformin treatment and
muscle Per2 showed a 12-h phase shift (Cosinor analysis, pb0.05)
(Fig. 3, Tables S2 and S3).
We then looked into the daily levels of clock gene expression (Fig. 3,
Table S3). Liver Per1, Per2 and Clock mRNA daily levels increased
1801M. Barnea et al. / Biochimica et Biophysica Acta 1822 (2012) 1796–1806(Student's t-test, pb0.01), indicating increased activity of the CLOCK:
BMAL1-mediated expression. Liver Bmal1 and Cry1 mRNA daily levels
decreased as a result of metformin treatment (Student's t-test, pb0.01).
These results were corroborated by a higher increase in the levels of
Rev-erbα (Student's t-test, pb0.01), the negative regulator of Bmal1
expression, than those of Rora, the positive regulator of Bmal1 expres-
sion (Fig. 3, Table S3). In themuscle, the daily levels ofmost genes were
reduced (Student's t-test, pb0.05), while Clock mRNA levels were
elevated (Student's t-test, pb0.05) and Bmal1 did not differ between
the groups (Fig. 3, Table S3).Fig. 5. Effect ofmetformin on circadian rhythms and averagemRNAand protein levels of the AM
levels. B. AMPK, LKB1, ACC, CK1ε and CK1α protein oscillation and daily average levels. Gastro
control (C, black circles and columns) or metformin-treated (Met, white circles and columns)m
by real-time PCR. Protein levels were analyzed by Western blotting and quantiﬁed using ac
respectively. Values are mean±SE, n=3 per time-point in each group. Asterisk denotes signiﬁ3.5. Effect ofmetformin onAMPK, LKB1, ACC and CKI in the liver andmuscle
To study the effect of metformin on metabolism, we ﬁrst measured
AMPKmRNA and protein levels. Liver AmpkmRNApeaked at the end of
the subjective night (Cosinor analysis, pb0.05) and metformin did not
affect the expression phase (Fig. 4A, Tables S2 and S3). AMPK protein
levels in control mice oscillated with a peak at CT2, whereas in the
metformin-treated group AMPK exhibited robust oscillation with a
peak at CT14 accompanied by a 40% increase in the amplitude (One-
way ANOVA, pb0.05) (Fig. 4B, Table S3). Liver AmpkmRNA daily levelsPKpathway in themuscle. A.Ampk, Lkb1,Acc and Ck1εmRNAoscillation and daily average
cnemius muscle was collected in total darkness every 3 h around the circadian cycle from
ice. Total RNAwas extracted, reverse-transcribed and expression levels were determined
tin as loading control. The white and gray bars designate the subjective day and night,
cant difference (pb0.05). CT, circadian time.
1802 M. Barnea et al. / Biochimica et Biophysica Acta 1822 (2012) 1796–1806were signiﬁcantly increased as well as pAMPK levels (Student's t-test,
pb0.01) (Fig. 4, Table S3) indicating increased activation of AMPK. In
the muscle, metformin treatment resulted in decreased Ampk mRNA
expression levels (Student's t-test, pb0.05), but increased amplitude
(Cosinor analysis, pb0.05) (Fig. 5A, Table S3). AMPK protein also
showed increased amplitude (Cosinor analysis, pb0.05) alongsideFig. 6. Effect ofmetforminonmetabolic genes expression in the liver andmuscle. Pgc1α,mPparα
in the liver and gastrocnemiusmuscle collected in total darkness every 3 h around the circadian
and columns) mice. Total RNA was reverse transcribed and its levels were determined by rea
designate the subjective day and night, respectively. Values are mean±SE, n=3 per time-poinelevated daily levels of AMPK and pAMPK protein (Fig. 5B, Table S3).
In addition, metformin treatment resulted in a phase delay of 6 h in
mRNA and 9 h in protein expression (Fig. 5, Tables S2 and S3).
We thenmeasured themRNA and protein levels of theAMPK kinase,
LKB1. In the absence of metformin, liver Lkb1 mRNA displayed a bi-
phasic expression with peaks at CT1 and CT13, while protein levels did,mPepck,mAdipor1 andmAdipor2mRNAoscillation anddaily average levelsweremeasured
cycle from control (C, black circles and columns) or metformin-treated (Met, white circles
l-time PCR. For total daily levels, all time-points were averaged. The white and gray bars
t in each group. Asterisk denotes signiﬁcant difference (pb0.05). CT, circadian time.
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Fig. 7. Effect of metformin on metabolism and the circadian clock. Metformin blocks mitochondria Complex I leading to increased NADH and AMP levels. This increase results in CLOCK:
BMAL1 promoter binding, which leads to phase advance. High AMP levels activate AMPK, which phosphorylates CKI leading to PER protein degradation and relief of CLOCK:BMAL1
inhibition. This relief causes increased CLOCK:BMAL1-mediated transcription, which, in turn, leads to a phase advance. AMPK also phosphorylates and, thus, inhibits ACC leading to
increased fatty acid oxidation and decreased fatty acid synthesis. AMPK activates SIRT1 and NAMPT, which leads to increased levels of NAD+. High levels of NAD+ reduce CLOCK:BMAL1
promoter binding, which leads to a phase delay. The tissue-speciﬁc balance between NAMPT and AMPK activities determines the phase shift in the clock.
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(Fig. 4, Table S2).Metformin resulted in a 5-h phase advance of liver Lkb1
mRNA and induced a signiﬁcant bi-phasic expression of LKB1 protein
(Cosinor analysis, pb0.01) (Fig. 4, Table S2). The dailymRNA levels were
increased 4-fold after metformin treatment (Student's t-test, pb0.01)
(Fig. 4A, Table S3). Total LKB1 protein daily levels did not differ between
the groups, but pLKB1 levels were signiﬁcantly increased in the
metformin group (Student's t-test, pb0.01) (Fig. 4B), indicating
increased activation of LKB1. In the muscle, Lkb1 mRNA and LKB1
protein exhibited a bi-phasic rhythm (Cosinor analysis, pb0.01). Met-
formin treatment resulted in the loss of daily rhythmicity of both mRNA
and protein (Fig. 5). Total LKB1 remained unchanged after metformin
treatment (Student's t-test, p>0.05), although pLKB1 levels showed a
non-signiﬁcant 18% increase (Student's t-test, p=0.067) (Fig. 5B).
We next measured the mRNA and protein levels of the AMPK sub-
strate, ACC. AccmRNA exhibited a daily oscillation with a peak at CT23,
while metformin treatment resulted in a 3-h phase advance (Cosinor
analysis, pb0.05) (Fig. 4A, Tables S2 and S3). ACC protein did not
oscillate in the control group, while metformin resulted in a signiﬁcant
daily rhythm with a peak at CT8. Acc mRNA, ACC and pACC protein
daily levels were signiﬁcantly increased in the metformin group
(Student's t-test, pb0.01) (Fig. 4). In the muscle, AccmRNA levels of
the control group oscillated with a peak at CT5 (Cosinor analysis,
pb0.05), while in the metformin group Acc did not exhibit circadianrhythm (One-way ANOVA, p>0.05) (Fig. 5A). Like in the liver, ACC
protein did not oscillate in the muscle of control mice, but oscillation
was induced by metformin treatment with a peak at CT14. The daily
levels of Acc mRNA, ACC and pACC protein decreased following
metformin administration (Student's t-test, pb0.05), suggesting
inhibited fatty acid synthesis (Fig. 5, Table S3).
We also measured the mRNA and protein levels of another AMPK
substrate, CKIε, the kinase that phosphorylates the PER proteins and
directs them for degradation. Liver CkIε mRNA exhibited a signiﬁcant
oscillation only in the metformin group (One-way ANOVA, pb0.01).
mRNA levels were signiﬁcantly increased in the metformin group
(Student's t-test, pb0.01) (Fig. 4A). The protein levels did not oscillate
in both groups (One-way ANOVA, p>0.05) and the daily levels re-
mained unchanged (Fig. 4B). CKIα protein exhibited a daily rhythm
with a peak at CT2 (One-way ANOVA, pb0.05). Metformin treatment
resulted in a loss of CKIα oscillation (One-way ANOVA, pb0.05), while
its levels increased (Student's t-test, pb0.01) (Fig. 4B, Table S3). In the
muscle, similarly to the liver, CkIε mRNA levels exhibited a circadian
rhythm only following metformin administration with a peak at CT2
(Cosinor analysis, pb0.02) (Fig. 5A, Table S2). A similar effect of induced
oscillation followingmetformin treatmentwas observed in CKIε protein
levels. While CkIεmRNA levels did not differ between the groups, CKIε
protein levels increased (Student's t-test, pb0.05) in the metformin
group (Fig. 5). CKIα protein oscillationwas accompanied by a reduction
1804 M. Barnea et al. / Biochimica et Biophysica Acta 1822 (2012) 1796–1806in total protein levels in themetformin group (Student's t-test, pb0.05)
(Fig. 5).
3.6. Effect of metformin on PGC1α, PPARα, adiponectin receptors, and
PEPCK expression
In the liver, metformin administration resulted in the oscillation of
Pgc1a mRNA (One-way ANOVA, pb0.01), a key co-activator of PPARα,
while PparαmRNA did not oscillate (One-way ANOVA, p>0.05) (Fig. 6).
In the muscle, metformin treatment resulted in a 3-h phase delay and
decreased amplitude of Pgc1a (Cosinor analysis, pb0.05), and induced a
robust circadian rhythm of Ppara (One-way ANOVA, pb0.01) (Fig. 6,
Table S3). Both Pgc1a and Pparα daily mean levels were elevated in the
liver (Student's t-test, pb0.01), while in the muscle Ppara was reduced
(Student's t-test, pb0.01) and Pgc1a levels were not affected by
metformin. The phase of Pepck, a key gluconeogenic enzyme in the
liver, exhibited a 3-h phase advance (Cosinor analysis, pb0.05) and its
daily levels were slightly, but signiﬁcantly, elevated in the metformin-
treated group (Student's t-test, pb0.05) (Fig. 6, Table S3).
We next measured signaling of adiponectin, an adipokine that
leads to AMPK activation in the muscle and liver. The adiponectin
receptor Adipor1 mRNA did not exhibit daily rhythmicity in the liver
(One-way ANOVA, p>0.05), while AdipoR2 mRNA exhibited marked
oscillation (One-way ANOVA, pb0.01) and metformin administration
resulted in a 3-h phase advance (Fig. 6, Table S3). There was also a
55% increase in the mean daily levels of Adipor2 mRNA in the liver
(Student's t-test, pb0.01) (Fig. 6, Table S3). In the muscle, both re-
ceptors did not exhibit a daily rhythm (One-way ANOVA, p>0.05).
The levels of Adipor1mRNAwere signiﬁcantly elevated in metformin-
treated mice (Student's t-test, pb0.05) while Adipor2 mRNA levels
remained unchanged (Fig. 6, Table S3).
4. Discussion
In the current study, we investigated the effect of metformin
treatment on both metabolic and circadian rhythms. Although we
performed the experiment on young, lean healthy mice to avoid the
disruptive effect of obesity or diabetes on the circadian clock, our
results show profound tissue-speciﬁc effects on metabolic rhythms in
the liver and muscle.
4.1. Effect of metformin on overall metabolism
As the experiment was performed on lean and healthy mice, daily
food intake and body weight were not affected by metformin adminis-
tration. There was a slight reduction in water consumption, probably due
to the effect of metformin on thewater taste. Mean daily levels of insulin,
glucose and lipids in the serum were not affected after 6 weeks of met-
formin administration, as is expected in leanhealthymice. In contrast, the
daily levels of glucagon, referred to as a hypoglycemic signal [24], were
reduced. As glucagon secretion is inhibited by glucagon-like peptide 1
(GLP-1) [25], it is possible that metformin affected the small intestine to
secret more GLP-1 leading to reduced glucagon secretion, as has recently
been shown [26]. As it is well established that high glucagon levels act in
the short-term to reduce meal size [27], we should have expected in-
creased food intake and weight gain. However, in parallel, leptin levels
were elevated (Table 1). As leptin is a long-term anorexigenic signal [28],
the overall effect achieved in our experiment is that of satiety. This is
further reinforced by the reduced levels of AMPK and pAMPK in the
hypothalamus (Fig. 2), as reduced AMPK expression or activation in this
brain area has been shown to signal satiety [14]. It is noteworthy that as
the whole hypothalamus was analyzed it is possible that the various
regions, such as the lateral hypothalamus or ventromedial hypothalamus,
had opposing effects on AMPK levels. Thus, in lean healthy mice, the net
effect of metformin is maintenance of food intake and body weight.
Longer metformin treatment or treatment of obese and/or diabetic micemay have caused reduced food intake and, as a result, reduced body
weight, as has been reported [29,30].
At the cellular level,metformin led to AMPK activation, in the liver via
LKB1 and in the muscle by another kinase, presumably CaMKK [31].
Activation of ACC, the AMPK substrate, decreased in the liver as expected
by the rise in pAMPK levels (Fig. 4). In the muscle, the total levels of Acc
mRNA, ACC protein and its amplitude decreased, implying reduced ACC
activity. ACC reduced expression or inhibition leads to reduced fatty acid
synthesis and increased fatty acid oxidation (Fig. 7). In addition, in-
creased sensitivity to fatty acid and insulin was achieved, as reﬂected by
increased liver Pparα and Pgc1αmRNA levels and the robust increase in
muscle Pparα mRNA amplitude. Although AMPK activation has been
shown to inhibit gluconeogenesis [32], liver Pepck levels were slightly
elevated compared to the control group. These results can be explained
by the elevated Pparα and Pgc1αmRNA levels, as both PPARα and PGC1α
have been implicated in the regulation of Pepck expression [33,34]. The
elevated gluconeogenic activity would prevent hypoglycemia after
fasting, a well described attribute of metformin [35]. Metformin also
affected the expression of adiponectin receptors. AdipoR1, the abundant
isoforms in the muscle, and AdipoR2, the predominant isoform in the
liver, were each upregulated in their corresponding tissue. These results
suggest that metformin leads to increased tissue-speciﬁc adiponectin
receptor expression, which would signal activation of AMPK, fatty acid
oxidation and inhibited fatty acid synthesis once adiponectin binds to its
receptors [36]. Overall, the metabolic proﬁle shows increased fatty acid
oxidation, inhibited fatty acid synthesis and insulin sensitivity both in the
liver and the muscle.
4.2. Effect of metformin on circadian rhythms
Insulin, leptin, glucagon, ghrelin and triglycerides exhibited a clear
endogenous rhythm both in the control and metformin-treated mice
(Fig. 1). Leptin and ghrelin exhibited reciprocal rhythms with leptin
high in the inactive period and ghrelin high in the active period, as has
been previously described [37–39]. Insulin and leptin exhibited a phase
advance in the metformin-treated mice indicative of metformin effect
on the circadianmechanism.Metformin also induced oscillation of liver
Pgc1α and CkIε and muscle Pparα, rendering a more robust circadian
proﬁle. This further demonstrates the effect of metformin on the circa-
dian mechanism. Synchronization of metabolic functions leads eventu-
ally to a healthier phenotype [40]. Indeed, activated LKB1 and CK1were
previously indicated to be involved in tumor suppression [41] and
cancer development [42], while metformin has recently been investi-
gated as a putative enhancer of chemotherapy [43].
Recently it has been shown that metformin crosses the blood–brain
barrier and accumulates in the brain of rodents [44]. Our results indicate
that metformin does not affect the period of the central circadian clock
located in the SCN, as reﬂected by no change in locomotor activity, a
direct readout of the central circadian clock. However, assessment of
the circadian expression of the core clock mechanism and metabolic
genes in the peripheral tissues revealed that metformin has tissue-
speciﬁc effects.
In the liver, most clock andmetabolic genes showed a phase advance
as a result of metformin treatment. The elevated AMPK activity by met-
formin results in a shortened half-life of the negative feedback loop and
increased activity of the positive-loop of the circadian clock [6]. Most
recently, it has been shown that AMPK enhances the activity of SIRT1, an
NAD+-dependent histone deacetylase, by increasing cellular NAD+
levels, resulting in the deacetylation and modulation of the activity of
downstream SIRT1 targets, such as PPARγ and PGC-1α, key factors that
regulate the core molecular clock [45]. Activated SIRT1 also deacetylates
BMAL1, PER2, and histones [46] leading to relief of PER:CRY-mediated
inhibition and promoting a phase advance. These results are in
agreement with our previous report that fasting, which also leads to
AMPK and SIRT1 activation, resulted in phase advances [20]. Although
the levels of liver CKIε, the kinase that phosphorylates the PER proteins
1805M. Barnea et al. / Biochimica et Biophysica Acta 1822 (2012) 1796–1806leading to their degradation, remained unchanged, CKIα protein levels
were elevated. Indeed, it has been recently reported that othermembers
of the CKI family are involved in regulation of the clockmechanism [47].
The phase advancemediated bymetformin can also be explained by the
ﬁnding that metformin treatment results in reduced cellular redox
potential, possibly through inhibition of Complex I in the mitochondria
[48]. Inhibition of the respiratory chain would lead to increased levels of
reduced nicotinamide adenine dinucleotide (NADH). As CLOCK and
BMAL1bind efﬁciently to E-box sequences in the presence of highNADH
[49], increased NADH levels, as a result of metformin treatment, would
lead to enhanced activity of CLOCK:BMAL1-mediated expression (Fig. 7).
Indeed, metformin resulted in increased daily levels of Per1 and Per2
mRNA in the liver. In parallel, Clock expression also increased. Therewas
a decrease in Bmal1 and Cry1 expression, presumably as a result of the
marked increase in Rev-erbα, a known repressor of both genes [4,50].
In the muscle, while some genes presented a phase advance, simi-
larly to the liver, others exhibited a phase delay. This implies a circadian
regulatory mechanism slightly different than that of the liver. The
increasedmuscle pAMPKandCKIεprotein levels, the kinase responsible
for PER proteins phosphorylation and degradation, support AMPK
involvement in the circadian clock mechanism, similarly to what has
been found in the liver. However, it was recently demonstrated that
AMPK activation in the muscle, e.g., by metformin, leads to the activa-
tion of nicotinamide phosphoryl-transferase (NAMPT), the rate limiting
enzyme in NAD+ synthesis [45,51]. In addition, SIRT1, which is acti-
vated by AMPK, is recruited to the Nampt promoter and contributes to
the circadian synthesis of its own coenzyme [52]. In turn, high NAD+
levels inhibit DNA binding of CLOCK:BMAL1, which results in decreased
expression and reduced daily levels of Per1, Per2 and other clock-
controlled genes, aswe have found in this study. Thus, in themuscle,we
have a dual effect of metformin, inhibition of Complex I, which leads to
increased NADH levels, and activation of NAMPT, which leads to in-
creasedNAD+ levels. However, unlikemetformin,which increases both
NAD+ and NADH levels, activation of SIRT1 alone leads to an increase
only in NAD+ levels. This dual effect after metformin treatment results
in a more complex effect on CLOCK:BMAL1-mediated expression lead-
ing to an overall higher ratio of NAD+/NADH, resulting, in turn, mainly
in phase delays.
Although NAMPT activation may also be a factor in the liver, the
balance between both effects achieved with metformin treatment
possibly determines the phase of circadian rhythms in a tissue-speciﬁc
manner (Fig. 7). Althoughmetformin affected circadian rhythms differ-
ently in the liver vs. in the muscle, it had the same overall effect on
metabolism in both tissues. As genes are expressed at different levels in
the liver vs. in themuscle, e.g., NAMPT, AMPK or SIRT1, it seems that the
differential effect on circadian rhythmicity as a result of metformin
treatment is unavoidable. However, as each peripheral tissue has a
slightly different endogenous phase of clock gene expression [53], the
effect seen with metformin should not reﬂect a pathophysiological
situation. This is corroborated by the same overall metabolic effect
shown in both tissues. In addition, it was recently shown that AMPK
activity was decreased in white adipose tissue (WAT) of high-fat-fed
mice, in association with suppressed expression of the core circadian
component the CLOCK protein [54]. However, metformin opposed this
effect and led to both AMPK activation and increased CLOCK expression,
as was found in this study.
5. Conclusions
Metformin induces the activation of AMPK either by LKB1 in the
liver and/or by other kinases, such as CaMKK, in the muscle. In turn,
AMPK phosphorylates both ACC and CKI enzymes leading to fatty acid
oxidation and enhanced activity of the positive loop of the circadian
clock, respectively. This drives the expression of both clock and
metabolic genes. The different NAD+/NADH ratios may explain the
differences in circadian expression phase in the liver vs. in the muscle.Author contribution
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